Clinical Trial Update: Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance

View source ↗

Summary

Biogen's AVONEX preventive study in high-risk multiple sclerosis participants has been terminated and is under ongoing neurological surveillance.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Avonex (Interferon beta-1a)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis | Status: TERMINATED